PRZOOM - /newswire/ -
London, United Kingdom, 2013/12/11 - According to the latest research findings by the independent London-based global research firm TechNavio, increasing growth of the Global Epigenetics Market is due to the growing instances of cancer among patients in developed and developing countries.
The findings are for the forecast period 2014-2018.
The Global Epigenetics market will be witnessing double-digit growth due to a number of supportive factors, which includes the increase in aging population, the huge amount of funds and investments, and the increased use of epigenetic drugs in the treatment of oncology indications.
Epigenetics is gaining importance as a promising scientific approach for understanding the influence of the epigenetic mechanisms in cancer and various other diseases. Rapid advancements have been occurring specifically in the field of cancer therapeutics. Epigenetic drugs are also finding application in non-oncological fields such as inflammatory diseases, autoimmune diseases, neurodegenerative disorders, and personalized medicine.
Drug manufacturers are focusing on the development of epigenetic drugs for the treatment of cancers and other diseases. Globally, there are a few players dominating this market that include Celgene Corp., Eisai Inc. and Merck & Co. Inc. Due to the numerous patent expiries of major branded drugs in this market; the competition is expected to be characterized by consolidation activities, partnerships, and intensive mergers and acquisitions.
To determine the scenario for these vendors in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in order of importance.
TechNavio (technavio.com) is a leading technology research and advisory company with a global coverage. We focus on emerging technology trends that can shape the market. We identify and explain these trends to our customers to help them take better decisions.
TechNavio models the trends using a mix of quantitative and qualitative tools in its proprietary research methodologies. We build forecasts across market segments and geographies based on the trends identified. These forecasts and analysis are used to help our customers identify new and existing opportunities in their markets. We also help customers assess their competitive position in a changing market scenario.
TechNavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape of Global Epigenetics Market. Our analysts obtain the information using a combination of the bottom-up and top-down approaches, besides using in-house market modeling tools. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
Decision makers and influencers in sales & marketing, strategy, product and R&D teams rely on research from TechNavio. We have a large and growing base of happy customers worldwide. Our customers include technology suppliers, end users, consulting companies, investment firms and research institutes.
Founded in 2003, TechNavio has about 200 analysts globally. We cover more than 500 technologies across 80 countries. Our analysts are closely monitoring the market every day by talking to all the industry participants. We have proprietary databases that provide us with a complete perspective of the market. TechNavio develops over 2000 pieces of research deliverables every year.